June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Characterising individuals with retinopathy from retinal image grading data in UK Biobank
Author Affiliations & Notes
  • Alasdair Warwick
    Institute of Cardiovascular Science, University College London, London, London, United Kingdom
    Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Barbra Hamill
    Centre for Public Health, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
  • Katie Curran
    Centre for Public Health, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
  • Anthony Khawaja
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Andrew J Lotery
    Division of Clinical and Experimental Sciences, University of Southampton, Southampton, Hampshire, United Kingdom
    Medical Retina, University Hospital Southampton NHS Foundation Trust, Southampton, Southampton, United Kingdom
  • Paul Foster
    Joint Library of Ophthalmology Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, London, United Kingdom
    Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Konstantinos Balaskas
    Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Michael Joseph Quinn
    Centre for Public Health, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
  • Savita Madhusudhan
    St Paul's Eye Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, Liverpool, United Kingdom
  • Alan Sproule
    Centre for Public Health, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
  • Sophie Leach
    St Paul's Eye Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, Liverpool, United Kingdom
  • Daniela Florea
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Muldrew Alyson
    Centre for Public Health, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
  • Laura Cushley
    Centre for Public Health, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
  • Graham Young
    Centre for Public Health, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
  • Tunde Peto
    Centre for Public Health, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
    Medical Retina, Belfast Health and Social Care Trust, Belfast, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships   Alasdair Warwick None; Barbra Hamill None; Katie Curran None; Anthony Khawaja Abbvie, Code C (Consultant/Contractor), Aerie, Code C (Consultant/Contractor), Google Health, Code C (Consultant/Contractor), Novartis, Code C (Consultant/Contractor), Reichert, Code C (Consultant/Contractor), Santen, Code C (Consultant/Contractor), Thea, Code C (Consultant/Contractor); Andrew Lotery None; Paul Foster None; Konstantinos Balaskas Roche, Novartis , Code C (Consultant/Contractor), Roche, Novartis, Bayer, Apellis , Code F (Financial Support), Novartis, Bayer, Roche, Alimera, Heidelberg Engineering, Code R (Recipient); Michael Quinn None; Savita Madhusudhan None; Alan Sproule None; Sophie Leach None; Daniela Florea None; Muldrew Alyson None; Laura Cushley None; Graham Young None; Tunde Peto Optos, Code C (Consultant/Contractor), Optomed, Code C (Consultant/Contractor), Allergan, Genentech/Roche, Oxurion, Novartis, Bayer, Heidelberg, Optos, Apellis, Alimera, Bayer |, Code R (Recipient)
  • Footnotes
    Support  Wellcome Trust grant 220558/Z/20/ Z
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 814. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alasdair Warwick, Barbra Hamill, Katie Curran, Anthony Khawaja, Andrew J Lotery, Paul Foster, Konstantinos Balaskas, Michael Joseph Quinn, Savita Madhusudhan, Alan Sproule, Sophie Leach, Daniela Florea, Muldrew Alyson, Laura Cushley, Graham Young, Tunde Peto; Characterising individuals with retinopathy from retinal image grading data in UK Biobank. Invest. Ophthalmol. Vis. Sci. 2022;63(7):814.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aims of this study were to identify individuals from the UK Biobank (UKBB) cohort with detectable retinopathy on retinal imaging and to describe their sociodemographic and clinical characteristics.

Methods : Colour fundus photographs and macular optical coherence tomography (OCT) scans were acquired using a Topcon 3D OCT-1000 Mark II system (Topcon, Japan). Grading was performed by trained and certified graders and clinicians of the Network of Ophthalmic Reading Centres UK (NetwORC UK-Belfast, Liverpool, and Moorfields Ophthalmic Image Reading Centres). Retinopathy was defined as the presence of one or more microaneurysms in either eye, with or without other retinal microvascular abnormalities on either imaging modality. Diagnosed diabetes (DM), diabetic retinopathy (DR) and hypertension (HTN) were ascertained from self-reported (verbal interview), linked hospital episode statistics and primary care records at the time of imaging. Self-reported medication history was obtained from touchscreen questionnaire responses. HbA1c >48mmol/mol was considered diagnostic of DM. Systolic or diastolic blood pressure (BP) measurements ≥140mmHg and ≥80mmHg respectively were considered diagnostic of HTN.

Results : Among 68,517 UKBB participants who underwent fundus imaging, 265 (0.4%) individuals were identified to have retinopathy from retinal imaging. The median age at assessment for this group was 59 years (interquartile range 52-64), 70.9% were men and 79.6% were of white ethnic background. When retinopathy grading data were compared against medical records, 69.8% and 49.8% had a diagnosis of DM and DR respectively. The majority (55.5%) had a HbA1c level in the diagnostic range for DM (mean 54.5 mmol/mol) and 47.2% self-reported using insulin. A diagnosis of HTN was recorded for 59.2%, while 55.1% self-reported taking anti-hypertensive medication and 73.6% had BP measurements in the hypertensive range. Overall, 95.1% had either DM or HTN (diagnosed or undiagnosed), while 63.0% had both. Of the 13 (4.9%) individuals without DM or HTN, 7 had only a single microaneurysm in one eye.

Conclusions : This is one of the largest prospective cohort studies containing validated grading data for retinopathy, showing a high prevalence of both DM and or HTN. These results demonstrate the quality of the retinal image grading and highlight the potential for detecting systemic pathology.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×